Clinical Trials Logo
  1. Home
  2. Tongue Cancer
  3. NCT03008330
  4. Details
NCT03008330 Clinical Trial

High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer

Tongue Cancer Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03008330
Other study ID # HANK-tongue
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date December 1, 2016
Est. completion date June 1, 2019

Study information
Verified date December 2018
Source Fuda Cancer Hospital, Guangzhou
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of tongue cancer.

Description:

By enrolling patients with small metastases of tongue cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Recruitment information / eligibility
Status Completed
Enrollment 20
Est. completion date June 1, 2019
Est. primary completion date December 1, 2017
Accepts healthy volunteers No
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria:

- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence

- Body tumor 1-6, the maximum tumor length < 2 cm

- KPS = 70, lifespan > 6 months

- Platelet count = 80×109/L,white blood cell count = 3×109/L, neutrophil count = 2×109/L, hemoglobin = 80 g/L

Exclusion Criteria:

- Patients with cardiac pacemaker

- Patients with brain metastasis

- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• High-activity natural killer
Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.

Locations
Country Name City State
China Fuda cancer institute of Fuda cancer hospital Guangzhou Guangdong

Sponsors (2)
Lead Sponsor Collaborator
Fuda Cancer Hospital, Guangzhou Shenzhen Hank Bioengineering Institute

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Relief degree of tumors It will be evaluated by the Response Evaluation Criteria in Solid Tumors(RECIST) 3 months
Secondary Progress free survival(PFS) 1 year
Secondary Overall survival(OS) 3 years
See also
  Status Clinical Trial Phase
Completed NCT01469429 - Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Phase 1/Phase 2
Withdrawn NCT04041141 - Oral Stent Device for Radiation Treatments of Oral Cancers
Completed NCT00049283 - Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Phase 1
Completed NCT00407810 - Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT00096512 - S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT01637194 - Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Phase 1
Completed NCT00033618 - Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Phase 2
Completed NCT01816841 - Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed NCT04059861 - Ultrasound in Tongue Cancer- a Help to Decide Depth of Invasion and to Improve the Surgical Margin N/A
Recruiting NCT01854021 - Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer N/A
Withdrawn NCT01674374 - Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy Phase 2
Completed NCT01816984 - PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 1/Phase 2
Terminated NCT01528137 - Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Phase 1
Completed NCT04337853 - Radiotherapy of Tongue Cancer Using an Intraoral Stent Phase 1
Completed NCT01806675 - 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Phase 1/Phase 2
Active, not recruiting NCT01847326 - Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer Phase 1
Terminated NCT02177838 - Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer N/A
Completed NCT00114283 - Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Phase 2
Completed NCT04126226 - Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy N/A